Featured Story | By Ben Adams Hoping to make gene therapies safer and looking to move on from a troubled 18 months, Pfizer is putting down as much as $630 million in an upfront/milestone-based payment for Voyager’s next-gen gene therapies. read more |
| |
|---|
|
Top Stories By Ben Adams After a short tenure at Gilead running its cancer R&D, Valeria Fantin, Ph.D., has been poached by French Big Pharma Sanofi. read more By Nick Paul Taylor Takeda has hit the brakes hard on its narcolepsy program in response to a safety signal, stopping its two midphase clinical trials months before their planned completion dates. read more Sponsored By: Taconic Biosciences Pressure to get results in drug discovery and development is unprecedented and the need for genetically engineered custom mouse models is greater than ever. Innovative thinking is getting these critical models into researchers hands faster. read more By Nick Paul Taylor EQRx has identified a partner to support its effort to slash the price of medicines, teaming up with newly public drug and target discovery shop Absci to advance affordable protein-based therapeutics. read more Sponsored by: Almac Group PanCan utilised Almac's IRT expertise to accelerate their adaptive platform outcomes and improve patient care. Find out how here. read more By Kyle LaHucik Retrotope's lead candidate missed the primary endpoint in a late-stage trial of patients with an ultrarare and fatal genetic disease called infantile neuroaxonal dystrophy. The drug did statistically improve overall survival and progression free survival, so the California biotech will move forward with speaking to the FDA about its regulatory pathway. read more By Anastassia Gliadkovskaya The nonprofit is called Graphite Health, and it intends to build a standardized data platform for members as well as a marketplace that will feature accessible software and digital tools for health systems and patients. read more By Angus Liu Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in the U.S. by moving to new locations. read more By Andrea Park A tissue sample was taken from Lacks without her consent in 1951 and was subsequently used to develop the first polio vaccine, HPV vaccines, gene-mapping techniques and more. read more By Kyle LaHucik Contract research organization Syneos Health will buy artificial intelligence company RxDataScience to boost customer performance. The deal follows a September buy of StudyKIK. read more By Arlene Weintraub An oral dengue drug developed by Johnson & Johnson's Janssen unit and a Belgian team was effective in mouse models, drastically lowering the number of virus particles in the animals' blood within 24 hours of treatment, the researchers reported. J&J is moving the program into clinical development. read more Resources Sponsored By: Trial Interactive Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF. Sponsored By: Bioclinica This whitepaper addresses where AI can make the biggest impact in clinical trials. Sponsored by: Thermo Fisher Scientific Looking to accelerate your biotech company, but not sure where to start? Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: LabVantage Solutions Shift from data collection to data science. Add advanced analytics to your lab informatics platform to yield valuable, action-ready insights from LIMS and other data. Sponsored by: Thermo Fisher Scientific Integrate supply chain simulation into your early clinical trial planning to minimize risk in an uncertain supply chain environment, improve supply chain outcomes, and help streamline time-to-market for innovative therapies. Sponsored by: WCG Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
